BTIG Research Boosts Personalis (NASDAQ:PSNL) Price Target to $16.25

Personalis (NASDAQ:PSNL) had its target price boosted by analysts at BTIG Research from $11.00 to $16.25 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price objective would indicate a potential upside of 19.44% from the company’s previous close.

Several other equities analysts also recently commented on the company. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Needham & Company LLC downgraded Personalis from a “buy” rating to a “hold” rating in a research report on Monday. Lake Street Capital cut shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective for the company. in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Finally, Morgan Stanley boosted their price objective on Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $14.25.

Personalis Trading Down 11.6%

PSNL stock traded down $1.78 during trading on Monday, reaching $13.61. 8,604,430 shares of the stock were exchanged, compared to its average volume of 2,463,880. The stock has a 50 day simple moving average of $10.94 and a 200-day simple moving average of $8.91. Personalis has a twelve month low of $3.84 and a twelve month high of $16.39. The company has a market capitalization of $1.42 billion, a P/E ratio of -13.42 and a beta of 2.24.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The firm had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. Equities analysts predict that Personalis will post -1.07 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Aaron Tachibana sold 4,982 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $14.00, for a total value of $69,748.00. Following the completion of the transaction, the chief financial officer owned 198,833 shares in the company, valued at $2,783,662. This trade represents a 2.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,558,668.88. The trade was a 29.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 435,032 shares of company stock worth $5,599,929. 4.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd increased its stake in shares of Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after buying an additional 1,479 shares during the period. Deutsche Bank AG raised its holdings in Personalis by 4.5% during the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after acquiring an additional 1,655 shares during the period. Royal Bank of Canada increased its position in shares of Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares during the last quarter. Howland Capital Management LLC boosted its position in Personalis by 0.9% during the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after buying an additional 2,500 shares during the period. Finally, Intech Investment Management LLC boosted its position in Personalis by 23.4% during the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after buying an additional 3,851 shares during the period. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis News Roundup

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Tempus AI agreed to buy Personalis for about $1.5 billion, giving PSNL shareholders $16.25 per share and validating Personalis’ cancer-monitoring technology. Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
• Positive Sentiment: The acquisition expands Tempus’ minimal residual disease and precision oncology capabilities, underscoring strategic value for Personalis’ platform. Tempus to acquire Personalis for $1.5 billion
• Neutral Sentiment: Needham & Company LLC reaffirmed its “hold” rating on Personalis, suggesting analysts remain cautious despite the deal announcement. Benzinga report on Needham rating reaffirmation
• Negative Sentiment: Shareholder law firms announced investigations into whether the proposed sale to Tempus delivers a fair price, adding legal uncertainty around the transaction. Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Public Shareholders
• Negative Sentiment: Another shareholder alert said investors interested in potential claims should contact counsel regarding the proposed sale, reinforcing concern that the offer may be challenged. PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.